Susquehanna International Group LLP Grows Stock Holdings in Nautilus Biotechnology, Inc. $NAUT

Susquehanna International Group LLP increased its holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 1,710.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 890,949 shares of the company’s stock after purchasing an additional 841,749 shares during the period. Susquehanna International Group LLP’s holdings in Nautilus Biotechnology were worth $1,666,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of Nautilus Biotechnology during the 2nd quarter worth $5,025,000. Corient Private Wealth LLC raised its holdings in shares of Nautilus Biotechnology by 860.0% during the 2nd quarter. Corient Private Wealth LLC now owns 435,350 shares of the company’s stock valued at $316,000 after buying an additional 390,000 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Nautilus Biotechnology during the first quarter valued at approximately $194,000. Jane Street Group LLC lifted its holdings in Nautilus Biotechnology by 304.1% in the 2nd quarter. Jane Street Group LLC now owns 290,369 shares of the company’s stock worth $210,000 after buying an additional 218,512 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Nautilus Biotechnology by 152.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 297,437 shares of the company’s stock worth $580,000 after acquiring an additional 179,721 shares in the last quarter. Institutional investors and hedge funds own 50.71% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Nautilus Biotechnology has a consensus rating of “Hold” and a consensus target price of $4.00.

Insider Buying and Selling

In other Nautilus Biotechnology news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $2.35, for a total value of $11,750,000.00. Following the sale, the insider directly owned 971,885 shares in the company, valued at approximately $2,283,929.75. The trade was a 83.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 41.10% of the company’s stock.

Nautilus Biotechnology Stock Performance

NASDAQ:NAUT opened at $0.89 on Monday. The stock has a market cap of $112.71 million, a price-to-earnings ratio of -1.97 and a beta of 0.87. The business has a fifty day moving average of $1.41 and a 200-day moving average of $2.26. Nautilus Biotechnology, Inc. has a 1 year low of $0.62 and a 1 year high of $4.31.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings results on Tuesday, July 28th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.10 million.

Nautilus Biotechnology Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.